China's CARsgen jumps most in near 10 weeks on new drug application

CARsgen Therapeutics Holdings

18/10/2022 04:48

** Shares of solid tumors therapies developer CARsgen
Therapeutics Holdings Ltd  2171.HK  jump as much as 15.3% to
HK$12.50, their highest since Sept. 28
    ** Stock set for biggest daily pct rise since Aug. 11, if
gains hold, and is the top pct gainer in Hang Seng Composite
Index  .HSCI 
    ** Shanghai-based firm says National Medical Products
Administration of China has accepted New Drug Application for
its zevorcabtagene autoleucel (Zevor-cel)  urn:newsml:reuters.com:*:nFWN31I3FX
    ** Says Zevor-cel is a fully human, autologous B-cell
maturation antigen CAR T-cell therapy for treatment of multiple
myeloma, which is a fatal blood cancer 
    ** The Hang Seng Commerce & Industry Index  .HSNC  gains
0.8%, and healthcare index  .HSCIH  rises 1.7%
    ** The Hang Seng Composite Index  .HSCI  climbs 0.7% and the
benchmark Hang Seng Index  .HSI  is up 0.5%
    ** As of last close, the stock had dropped 60.7% this year
 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))